Long-term complete remission after severe pembrolizumab-induced immune-related encephalitis in metastatic lung adeno-squamous carcinoma: A case report
Immune checkpoint inhibitors became the treatment of choice, in monotherapy or in association with platinum-based doublet chemotherapy, in first-line therapy for advanced-stage non-small-cell lung cancer without oncogenic driver. Nevertheless, it can be associated with diverse immune-related adverse...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Respiratory Medicine Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S221300712300093X |
| _version_ | 1797771589236817920 |
|---|---|
| author | Rémy Quirynen Sebahat Ocak Fabrice Duplaquet Lionel Pirard |
| author_facet | Rémy Quirynen Sebahat Ocak Fabrice Duplaquet Lionel Pirard |
| author_sort | Rémy Quirynen |
| collection | DOAJ |
| description | Immune checkpoint inhibitors became the treatment of choice, in monotherapy or in association with platinum-based doublet chemotherapy, in first-line therapy for advanced-stage non-small-cell lung cancer without oncogenic driver. Nevertheless, it can be associated with diverse immune-related adverse events; several immune-related adverse events can also follow each other involving multiple organ systems, leading to immune checkpoint inhibitors discontinuation and immunosuppressive therapy that could compromise the prognosis of patients, with the exception of rare situations such as this clinical case.This case report illustrates a succession of immune-related adverse events including a rare and severe pembrolizumab-induced immune-related encephalitis in a patient with metastatic lung adeno-squamous carcinoma in whom we could observe a long-term and complete remission despite discontinuation of treatment and high-dose corticosteroids.In metastatic non-small-cell lung cancer, a disease with a poor initial prognosis, some patients can benefit from immune checkpoint inhibitors and can even now present a long-term and complete remission and this despite severe and rare immune-related adverse events, high-dose corticosteroids and an early discontinuation of treatment. |
| first_indexed | 2024-03-12T21:39:48Z |
| format | Article |
| id | doaj.art-c1d7cef78fde4285b5ac469acc9efb41 |
| institution | Directory Open Access Journal |
| issn | 2213-0071 |
| language | English |
| last_indexed | 2024-03-12T21:39:48Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Respiratory Medicine Case Reports |
| spelling | doaj.art-c1d7cef78fde4285b5ac469acc9efb412023-07-27T05:55:55ZengElsevierRespiratory Medicine Case Reports2213-00712023-01-0145101898Long-term complete remission after severe pembrolizumab-induced immune-related encephalitis in metastatic lung adeno-squamous carcinoma: A case reportRémy Quirynen0Sebahat Ocak1Fabrice Duplaquet2Lionel Pirard3Department of Pulmonology, CHU UCL Namur (Godinne Site), Avenue Docteur Gaston Thérasse 1, 5530, Yvoir, BelgiumDepartment of Pulmonology, CHU UCL Namur (Godinne Site), Avenue Docteur Gaston Thérasse 1, 5530, Yvoir, Belgium; Pole of Pulmonology, Institut de Recherche Expérimentale et Clinique UCL, Avenue Hippocrate 55, 1200, Woluwe-Saint-Lambert, BelgiumDepartment of Pulmonology, CHU UCL Namur (Godinne Site), Avenue Docteur Gaston Thérasse 1, 5530, Yvoir, BelgiumDepartment of Pulmonology, CHU UCL Namur (Godinne Site), Avenue Docteur Gaston Thérasse 1, 5530, Yvoir, Belgium; Corresponding author. Avenue Docteur Gaston Thérasse 1, 5530, Yvoir, Belgium.Immune checkpoint inhibitors became the treatment of choice, in monotherapy or in association with platinum-based doublet chemotherapy, in first-line therapy for advanced-stage non-small-cell lung cancer without oncogenic driver. Nevertheless, it can be associated with diverse immune-related adverse events; several immune-related adverse events can also follow each other involving multiple organ systems, leading to immune checkpoint inhibitors discontinuation and immunosuppressive therapy that could compromise the prognosis of patients, with the exception of rare situations such as this clinical case.This case report illustrates a succession of immune-related adverse events including a rare and severe pembrolizumab-induced immune-related encephalitis in a patient with metastatic lung adeno-squamous carcinoma in whom we could observe a long-term and complete remission despite discontinuation of treatment and high-dose corticosteroids.In metastatic non-small-cell lung cancer, a disease with a poor initial prognosis, some patients can benefit from immune checkpoint inhibitors and can even now present a long-term and complete remission and this despite severe and rare immune-related adverse events, high-dose corticosteroids and an early discontinuation of treatment.http://www.sciencedirect.com/science/article/pii/S221300712300093XNon-small-cell lung cancerImmune checkpoint inhibitorImmune-mediated neurological adverse eventComplete remission |
| spellingShingle | Rémy Quirynen Sebahat Ocak Fabrice Duplaquet Lionel Pirard Long-term complete remission after severe pembrolizumab-induced immune-related encephalitis in metastatic lung adeno-squamous carcinoma: A case report Respiratory Medicine Case Reports Non-small-cell lung cancer Immune checkpoint inhibitor Immune-mediated neurological adverse event Complete remission |
| title | Long-term complete remission after severe pembrolizumab-induced immune-related encephalitis in metastatic lung adeno-squamous carcinoma: A case report |
| title_full | Long-term complete remission after severe pembrolizumab-induced immune-related encephalitis in metastatic lung adeno-squamous carcinoma: A case report |
| title_fullStr | Long-term complete remission after severe pembrolizumab-induced immune-related encephalitis in metastatic lung adeno-squamous carcinoma: A case report |
| title_full_unstemmed | Long-term complete remission after severe pembrolizumab-induced immune-related encephalitis in metastatic lung adeno-squamous carcinoma: A case report |
| title_short | Long-term complete remission after severe pembrolizumab-induced immune-related encephalitis in metastatic lung adeno-squamous carcinoma: A case report |
| title_sort | long term complete remission after severe pembrolizumab induced immune related encephalitis in metastatic lung adeno squamous carcinoma a case report |
| topic | Non-small-cell lung cancer Immune checkpoint inhibitor Immune-mediated neurological adverse event Complete remission |
| url | http://www.sciencedirect.com/science/article/pii/S221300712300093X |
| work_keys_str_mv | AT remyquirynen longtermcompleteremissionafterseverepembrolizumabinducedimmunerelatedencephalitisinmetastaticlungadenosquamouscarcinomaacasereport AT sebahatocak longtermcompleteremissionafterseverepembrolizumabinducedimmunerelatedencephalitisinmetastaticlungadenosquamouscarcinomaacasereport AT fabriceduplaquet longtermcompleteremissionafterseverepembrolizumabinducedimmunerelatedencephalitisinmetastaticlungadenosquamouscarcinomaacasereport AT lionelpirard longtermcompleteremissionafterseverepembrolizumabinducedimmunerelatedencephalitisinmetastaticlungadenosquamouscarcinomaacasereport |